Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Commercial Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,647 |
Ending reported balance
After 2026-10-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 1,929 · Balance 67,303 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 1,668 · Balance 68,971 Row 3 · 2026-10-01 · Exercise / conversion · Acquired 2,527 · Balance 71,498 Row 4 · 2026-10-01 · Exercise / conversion · Acquired 1,292 · Balance 72,790 Row 5 · 2026-10-01 · Tax withholding · Disposed 3,143 · Balance 69,647 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-01 · Exercise / conversion · Disposed 1,929 · Balance 0 F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 1,668 · Balance 0 F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,105 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 2,527 · Balance 10,105 F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,754 |
Reported balance
After 2026-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-01 · Exercise / conversion · Disposed 1,292 · Balance 7,754 F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,292 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · derivative · entry 9 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,754 Underlying: Common Stock · 1,292 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,527 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · derivative · entry 8 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,105 Underlying: Common Stock · 2,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,668 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · derivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · derivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 3,143 | $174.75 | $549,239.25 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · nonDerivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,647 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000018 · wk-form4_1790974819.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,193 | $0.00 Strike: $28.37 | $0.00 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · derivative · entry 8 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,668 Underlying: Common Stock · 28,193 shares Expires 2033-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,412 | $0.00 Strike: $110.49 | $0.00 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · derivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,620 Underlying: Common Stock · 35,412 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 17,413 | $170.24 | $2,964,401.31 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · nonDerivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,374 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 35,364 | $169.63 | $5,998,926.17 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · nonDerivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,787 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 7,365 | $168.79 | $1,243,144.98 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,151 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,463 | $167.38 | $579,638.67 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,516 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 28,193 | $28.37 | $799,835.41 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 22:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 35,412 | $110.49 | $3,912,671.88 |
DisclosureSEC source: 0001871615-26-000016 · wk-form4_1786486956.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,293 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · derivative · entry 9 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,046 Underlying: Common Stock · 1,293 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,526 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · derivative · entry 8 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,632 Underlying: Common Stock · 2,526 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · derivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,668 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · derivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 3,141 | $170.77 | $536,388.57 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · nonDerivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,374 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:11 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000014 · wk-form4_1783030282.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:37 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000012 · wk-form4_1781642225.xml · derivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:37 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 594 | $129.82 | $77,113.08 |
DisclosureSEC source: 0001871615-26-000012 · wk-form4_1781642225.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,101 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:37 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000012 · wk-form4_1781642225.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2026 Filed May 26, 2026 21:38 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,406 | $0.00 Strike: $32.86 | $0.00 |
DisclosureSEC source: 0001871615-26-000010 · wk-form4_1779831478.xml · derivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 701 Underlying: Common Stock · 24,406 shares Expires 2033-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares subject to award vests each month during the two-year period thereafter. Read SEC document |
| May 22, 2026 Filed May 26, 2026 21:38 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 24,406 | $118.67 | $2,896,360.08 |
DisclosureSEC source: 0001871615-26-000010 · wk-form4_1779831478.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,034 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.55 to $118.97. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 22, 2026 Filed May 26, 2026 21:38 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 24,406 | $32.86 | $801,981.16 |
DisclosureSEC source: 0001871615-26-000010 · wk-form4_1779831478.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 5,091 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · derivative · entry 9 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,339 Underlying: Common Stock · 5,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,526 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · derivative · entry 8 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,158 Underlying: Common Stock · 2,526 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · derivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,335 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · derivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,857 Underlying: Common Stock · 1,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 4,750 | $91.15 | $432,962.50 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · nonDerivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,034 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 5,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:22 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000008 · wk-form4_1775164935.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 22:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000006 · wk-form4_1773787691.xml · derivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,402 Underlying: Common Stock · 1,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 22:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 15,426 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000006 · wk-form4_1773787691.xml · derivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 22:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 7,127 | $85.49 | $609,287.23 |
DisclosureSEC source: 0001871615-26-000006 · wk-form4_1773787691.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,571 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 22:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000006 · wk-form4_1773787691.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 22:48 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 15,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000006 · wk-form4_1773787691.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:33 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 18,744 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000004 · wk-form4_1773448429.xml · derivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,744 Underlying: Common Stock · 18,744 shares Expires not disclosed F1 · derivative.exercise_date: This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 2,526 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · derivative · entry 12 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,684 Underlying: Common Stock · 2,526 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 5,688 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · derivative · entry 11 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,688 Underlying: Common Stock · 5,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · derivative · entry 10 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,002 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.